Home > Browse Research > Life Sciences > Pharmaceuticals > Therapeutic Area > Respiratory/Pulmonary

Respiratory/Pulmonary: market research reports

Respiratory/Pulmonary market research reports and industry analysis

Non-Small-Cell Lung Cancer (Advanced Squamous): Several Novel Agents Are in the Later-Stage Pipeline, but Do Any Have the Potential to Improve Survival? 3/23/2012 \| published by: Decision Resources ... diagnosis, approximately 50% of these patients have advanced (stage IV) disease, and of these patients, about 30% have squamous-cell histology disease. The current mainstay of treatment for advanced squamous NSCLC in the first-line setting is ... \| read more...	$10,000.00
Respiratory Depression – Pipeline Review, H1 2012 3/19/2012 \| published by: Global Markets Direct ... for Respiratory Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Depression. 'Respiratory Depression - Pipeline Review, H1 2012' ... \| read more...	$500.00
Acute Respiratory Distress Syndrome – Pipeline Review, H1 2012 3/19/2012 \| published by: Global Markets Direct ... provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute ... \| read more...	$500.00
Cough – Pipeline Review, H1 2012 3/19/2012 \| published by: Global Markets Direct ... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cough. 'Cough - Pipeline Review, H1 2012' is built using data and information ... \| read more...	$500.00
R&D Trends: COPD – Simplified therapies are gaining traction 3/14/2012 \| published by: Datamonitor ... Earlier stages of the pipeline show more diversity, with numerous novel anti-inflammatory therapies seen in preclinical and Phase I development. Features and benefits Support R&D decision making by understanding the competitive dynamics of the pipeline. ... \| read more...	$3,800.00
Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis 3/1/2012 \| published by: BioSeeker Group AB ... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ... \| read more...	$5,175.00
Triple Analysis: Colorectal Cancer, Lung Cancer and Pancreatic Cancer 3/1/2012 \| published by: BioSeeker Group AB ... assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas. Below is a short ... \| read more...	$5,175.00
Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 2/29/2012 \| published by: GlobalData ... The report is an essential source of information and analysis on the global Pulmonary Embolism Therapeutics market. The report identifies the key trends shaping and driving the global Pulmonary Embolism Therapeutics market. The report also ... \| read more...	$3,995.00
Cystic Fibrosis – Pipeline Review, H1 2012 2/27/2012 \| published by: Global Markets Direct ... for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. 'Cystic Fibrosis - Pipeline Review, H1 2012' ... \| read more...	$500.00
Chronic Obstructive Pulmonary Disease: Which Clinical Attributes Present the Greatest Opportunity for Emerging Single-Inhaler Combinations to Erode the Dominance of Tiotropium? 2/17/2012 \| published by: Decision Resources ... effectively reduce exacerbations as a key unmet need in COPD treatment; interviewed thought leaders similarly emphasize this measure’s importance. Experts are hopeful that the fixed-dose combinations in development will demonstrate additive effects of the component ... \| read more...	$10,000.00
Hospital-acquired Infection Incidence - Trends in Taiwan 2/3/2012 \| published by: Frost & Sullivan ... surgical site infections . It provides in-depth geographical analysis of HAI incidence and trends in these countries. Key opinion leaders and infection control heads in Taiwan hospitals were interviewed to obtain their perceptions on the ... \| read more...	$6,000.00
Respiratory Syncytial Virus (RSV) Prophylactic - Pipeline Assessment and Market Forecasts to 2019 1/31/2012 \| published by: GlobalData ... to 2019”. The report is an essential source of information and analysis on the global Respiratory Syncytial Virus (RSV) Prophylactic market. The report identifies the key trends shaping and driving the global Respiratory Syncytial Virus ... \| read more...	$3,995.00
Acute Lung Injury - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury. 'Acute Lung ... \| read more...	$500.00
Lung Cancer - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. 'Lung Cancer - Pipeline Review, H1 2012' ... \| read more...	$500.00
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... pipeline. This report provides information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the ... \| read more...	$500.00
Respiratory Distress Syndrome - Pipeline Review, H1 2012 1/23/2012 \| published by: Global Markets Direct ... the therapeutic development for Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Distress Syndrome. 'Respiratory Distress ... \| read more...	$500.00
Upper Respiratory Tract Infections Global Clinical Trials Review, H1, 2012 1/16/2012 \| published by: GlobalData ... scenario. This report provides elemental information and data relating to the clinical trials on Upper Respiratory Tract Infections. It includes an overview of the trial numbers and their recruitment status as per the site of ... \| read more...	$1,000.00
Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2012 1/16/2012 \| published by: GlobalData ... provides elemental information and data relating to the clinical trials on Respiratory Distress Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ... \| read more...	$1,000.00
Pulmonary Drug Delivery Systems: Technologies and Global Markets 1/1/2012 \| published by: BCC Research ... at a compound annual growth rate (CAGR) of 14.3%. The market for metered dose inhalers (MDIs) was $12.5 billion in 2010 and will reach $14.4 billion by the end of 2011. BCC forecasts this market ... \| read more...	$5,450.00
Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 12/31/2011 \| published by: GlobalData ... essential source of information and analysis on the global Bronchitis Therapeutics market. The report identifies the key trends shaping and driving the global Bronchitis Therapeutics market. The report also provides insights on the prevalent competitive ... \| read more...	$3,500.00
Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2011 12/30/2011 \| published by: Global Markets Direct ... provides information on the therapeutic development for Neonatal Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neonatal ... \| read more...	$500.00
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 12/28/2011 \| published by: GlobalData ... to 2018”. The report is an essential source of information and analysis on the global IPF market. The report identifies the key trends shaping and driving the global IPF market. The report also provides insights ... \| read more...	$3,500.00
Market and Product Forecasts: COPD in China – Novel therapies to see patient potential limited by high cost 12/14/2011 \| published by: Datamonitor ... 2020, owing to its wide application across all disease severities. A number of novel products will increase the product offering on the market, with most pipeline products aimed at more severe patients. Introduction Access Datamonitor’s ... \| read more...	$11,400.00
COPD in China Forecast 12/14/2011 \| published by: Datamonitor ... 2020, owing to its wide application across all disease severities. A number of novel products will increase the product offering on the market, with most pipeline products aimed at more severe patients. Features and benefits ... \| read more...	$11,400.00
Cystic Fibrosis Market Info™ 2011 12/1/2011 \| published by: Drug Market Info ... discounted prior year report providing good value for clients not requiring the most current year of sales and prescription data. Cystic Fibrosis (CF) is a chronic, progressive, life-limiting autosomal recessive genetic disease that affects the ... \| read more...	$2,500.00

< prev 2 3 4 5 6 7 8 9 10 11 next >